purine has been researched along with Acute Lymphoid Leukemia in 8 studies
1H-purine : The 1H-tautomer of purine.
3H-purine : The 3H-tautomer of purine.
9H-purine : The 9H-tautomer of purine.
7H-purine : The 7H-tautomer of purine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL)." | 1.42 | Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. ( Bai, Y; Chen, H; Chen, J; Chen, S; Chen, Y; Ding, J; Ding, L; Du, A; Ferrando, A; Gu, L; Huang, X; Jin, L; Kang, H; Kirschner-Schwabe, R; Li, B; Li, H; Li, W; Liang, H; Lu, G; Lu, H; Ma, X; Shen, S; Tang, J; Tzoneva, G; von Stackelberg, A; Wang, S; Wu, T; Yang, JJ; Yang, M; Zhang, J; Zhou, BB, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tzoneva, G | 2 |
| Dieck, CL | 1 |
| Oshima, K | 1 |
| Ambesi-Impiombato, A | 1 |
| Sánchez-Martín, M | 1 |
| Madubata, CJ | 1 |
| Khiabanian, H | 1 |
| Yu, J | 1 |
| Waanders, E | 1 |
| Iacobucci, I | 1 |
| Sulis, ML | 1 |
| Kato, M | 1 |
| Koh, K | 1 |
| Paganin, M | 1 |
| Basso, G | 1 |
| Gastier-Foster, JM | 1 |
| Loh, ML | 1 |
| Kirschner-Schwabe, R | 2 |
| Mullighan, CG | 1 |
| Rabadan, R | 1 |
| Ferrando, AA | 1 |
| Li, B | 1 |
| Li, H | 1 |
| Bai, Y | 1 |
| Yang, JJ | 1 |
| Chen, Y | 1 |
| Lu, G | 1 |
| Ma, X | 1 |
| Wu, T | 1 |
| Li, W | 1 |
| Lu, H | 1 |
| Ding, L | 1 |
| Liang, H | 1 |
| Huang, X | 1 |
| Yang, M | 1 |
| Jin, L | 1 |
| Kang, H | 1 |
| Chen, S | 1 |
| Du, A | 1 |
| Shen, S | 1 |
| Ding, J | 1 |
| Chen, H | 1 |
| Chen, J | 1 |
| von Stackelberg, A | 1 |
| Gu, L | 1 |
| Zhang, J | 1 |
| Ferrando, A | 1 |
| Tang, J | 1 |
| Wang, S | 1 |
| Zhou, BB | 1 |
| Hedeland, RL | 1 |
| Hvidt, K | 1 |
| Nersting, J | 1 |
| Rosthøj, S | 1 |
| Dalhoff, K | 1 |
| Lausen, B | 1 |
| Schmiegelow, K | 1 |
| Mikkelsen, TS | 1 |
| Sparreboom, A | 1 |
| Cheng, C | 1 |
| Zhou, Y | 1 |
| Boyett, JM | 1 |
| Raimondi, SC | 1 |
| Panetta, JC | 1 |
| Bowman, WP | 1 |
| Sandlund, JT | 2 |
| Pui, CH | 2 |
| Relling, MV | 2 |
| Evans, WE | 2 |
| KARAMCHANDANI, PV | 1 |
| GHARPURE, VV | 1 |
| NAIDU, VR | 1 |
| LAW, LW | 1 |
| TAORMINA, V | 1 |
| BOYLE, PJ | 1 |
| Masson, E | 1 |
| Synold, TW | 1 |
| Schuetz, JD | 1 |
| De Abreu, RA | 1 |
| Lambooy, LH | 1 |
| Ahment, K | 1 |
| Brouwer, C | 1 |
| Keizer-Garritsen, JJ | 1 |
| Bokkerink, JP | 1 |
| Trijbels, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent, and Adult Lymphoblastic Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia[NCT02912676] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
1 review available for purine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute lymphoblastic leukemia. Association with low (thio)purine enzyme activity.
Topics: Antimetabolites, Antineoplastic; Bone Marrow; Child; Humans; Mercaptopurine; Methyltransferases; Pre | 2000 |
2 trials available for purine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child, Preschool; Drug Administration Schedule; Humans; | 2011 |
Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia.
Topics: Adolescent; Allopurinol; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combi | 1996 |
5 other studies available for purine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Topics: 5'-Nucleotidase; Animals; Cell Proliferation; Clonal Evolution; Disease Models, Animal; Drug Resista | 2018 |
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
Topics: Adolescent; Child; Child, Preschool; Exome; Feedback, Physiological; Female; High-Throughput Nucleot | 2015 |
DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytosol; DNA; Drug Monitori | 2010 |
6-Mercaptopurine in acute lymphocytic leukaemia.
Topics: Humans; Leukemia; Leukemia, Lymphoid; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1956 |
Response of acute lymphocytic leukemias to the purine antagonist 6-mercaptopurine.
Topics: Acute Disease; Humans; Leukemia; Leukemia, Lymphoid; Mercaptopurine; Precursor Cell Lymphoblastic Le | 1954 |